Long-term Real-world Survival Outcomes with Dual Immune Checkpoint Blockade in Synchronous Metastatic Renal Cell Carcinoma: Implications for the Design of Prospective Cytoreductive Nephrectomy Trials
Year: 2025
Type: article
Language: en
Topic: Renal cell carcinoma treatment
Authors and affiliations:
raw_author_name: Leo Bickley
raw_affiliation_strings: Cancer Dynamics Laboratory, Francis Crick Institute, London, UK
Specialist Centre for Kidney Cancer, Department of Urology, Royal Free London NHS Foundation Trust, London, UK
raw_author_name: Elisabeth E. Fransen van de Putte
raw_affiliation_strings: Department of Urology, Netherlands Cancer Institute, Amsterdam, The Netherlands
raw_author_name: Luna van den Brink
raw_affiliation_strings: Department of Imaging & Biomarkers, Cancer Centre Amsterdam, Amsterdam, The Netherlands
Department of Urology, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands
raw_author_name: Laura Marandino
raw_affiliation_strings: Renal and Skin Units, Royal Marsden NHS Foundation Trust, London, UK
raw_author_name: Johannes C. van der Mijn
raw_affiliation_strings: Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands
raw_author_name: Sofie Wilgenhof
raw_affiliation_strings: Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands
raw_author_name: Johannes V. van Thienen
raw_affiliation_strings: Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands
raw_author_name: John B.A.G. Haanen
raw_affiliation_strings: Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands
raw_author_name: Ekaterini Boleti
raw_affiliation_strings: Specialist Centre for Kidney Cancer, Department of Medical Oncology, Royal Free London NHS Foundation Trust, London, UK
raw_author_name: Thomas Powles
raw_affiliation_strings: Barts Cancer Institute, Queen Mary University, London, UK
Specialist Centre for Kidney Cancer, Department of Medical Oncology, Royal Free London NHS Foundation Trust, London, UK
raw_author_name: Patricia J. Zondervan
raw_affiliation_strings: Department of Imaging & Biomarkers, Cancer Centre Amsterdam, Amsterdam, The Netherlands
Department of Urology, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands
raw_author_name: Niels M. Graafland
raw_affiliation_strings: Department of Urology, Netherlands Cancer Institute, Amsterdam, The Netherlands
Renal Cancer Network, Amsterdam, The Netherlands
raw_author_name: Zayd Tippu
raw_affiliation_strings: Cancer Dynamics Laboratory, Francis Crick Institute, London, UK
Renal and Skin Units, Royal Marsden NHS Foundation Trust, London, UK
raw_author_name: Samra Turajlic
raw_affiliation_strings: Cancer Dynamics Laboratory, Francis Crick Institute, London, UK
Renal and Skin Units, Royal Marsden NHS Foundation Trust, London, UK
raw_author_name: Axel Bex
raw_affiliation_strings: Department of Urology, Netherlands Cancer Institute, Amsterdam, The Netherlands
Division of Surgery and Interventional Science, University College London, London, UK
Renal Cancer Network, Amsterdam, The Netherlands
Specialist Centre for Kidney Cancer, Department of Urology, Royal Free London NHS Foundation Trust, London, UK